Sign Up Now to Download a Free Research Report on

Sign-Up to Get the Equity Report on this Company Plus Exclusive Access to Our Winning Newsletter Alerts




Download Adobe Reader Having problems viewing PDF files? Download Adobe Reader.

Dendreon Corporation

Dendreon shares soared 21 percent on more six-times the average daily volume Friday. Sanford C. Bernstein & Co. analyst Geoffrey Porges recently raised his peak revenue forecast for Provenge, the company’s prostate cancer drug, to $799 million by 2017, his previous forecast was $580 million.

Going forward ... (see research report)



RESEARCH REPORT ON Download Free Report Now


Preview Pages of Actual Equity Report

Download Adobe Reader Having problems viewing PDF files? Download Adobe Reader. Research Report on    Research Report on    Research Report on    

Research Report on    Research Report on    Research Report on